1358783-18-2

Usage

Uses

Used in Drug Discovery:
Tert-butyl 4-benzyl-octahydropyrrolo[3,4-b]morpholine-6-carboxylate is used as a lead compound for drug discovery due to its unique structure and potential biological activity. Its complex molecular architecture allows for the exploration of various interactions with biological targets, which may lead to the development of new therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl 4-benzyl-octahydropyrrolo[3,4-b]morpholine-6-carboxylate is utilized as a building block or a scaffold for the synthesis of novel bioactive molecules. Its structural elements can be modified to create derivatives with improved pharmacological properties, such as enhanced potency, selectivity, and reduced side effects.
Used in Chemical Research:
Tert-butyl 4-benzyl-octahydropyrrolo[3,4-b]morpholine-6-carboxylate serves as a subject of study in chemical research to understand its reactivity, stability, and potential interactions with other molecules. This knowledge can contribute to the advancement of synthetic methodologies and the design of new chemical entities with specific applications in various industries.
Used in Pharmaceutical Industry:
Tert-butyl 4-benzyl-octahydropyrrolo[3,4-b]morpholine-6-carboxylate is used as an intermediate in the synthesis of pharmaceutical compounds. Its unique structural features can be leveraged to create new drugs with improved therapeutic profiles, including better efficacy, safety, and pharmacokinetic properties.
Used in Biochemical Research:
In biochemical research, tert-butyl 4-benzyl-octahydropyrrolo[3,4-b]morpholine-6-carboxylate is employed as a tool to probe the mechanisms of biological processes and to identify potential targets for therapeutic intervention. Its interactions with biomolecules can provide insights into the molecular basis of diseases and the development of new treatment strategies.

Upstream product

• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1358783-16-0 tert-butyl 3-bromo-4-{2-[(4-methylbenzenesulfonyl)oxy]-ethoxy}pyrrolidine-1-carboxylate 
• 100-46-9 benzylamine 
• 1358783-14-8 3-bromo-4-(2-hydroxyethoxy)pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1438075-59-2 6-(3-(4-benzylhexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl)propoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine 
• 1360364-21-1 tert-butyl 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazine-6-carboxylate 
• 775251-20-2 4-methyl-3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazine 

Relevant academic research and scientific papers

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG

Disclosed is a substituted 2H-pyrazole derivative serving as a selective CDK4/6 inhibitor. Specifically, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof which serves as a selective CDK4/6 inhibitor.

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

4-quinazoline amine derivatives and their use

A 4-quinazoline amine derivative as represented by formula (1), a pharmaceutical composition comprising the derivative, and an application thereof in preparing medicine for curing cancer. The cancer is a drug-resistant cancer, preferably a cancer resisting an EGFR reversible inhibitor, and more preferably, a cancer resisting gefitinib, erlotinib or lapatinib; alternatively, the cancer carries EGFR mutation.

Azaquinazoline Inhibitors Of Atypical Protein Kinase C

The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disor

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.